Show
Sort by
-
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR : a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
-
Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease : a cross-sectional analysis of ten population-based studies
-
The low flyers : persistent airflow limitation in young adults
-
Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease : a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
-
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE) : an open-label extension study
-
Small airway loss in the physiologically ageing lung : a cross-sectional study in unused donor lungs
-
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE) : a randomised, double-blind, placebo-controlled, phase 3 trial
-
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN) : a double-blind, randomised, phase 3A trial
-
Mepolizumab for chronic rhinosinusitis with nasal polyps
-
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial